Investor Presentaiton
Conclusions
Daiichi-Sankyo
The robust response rates and survival outcomes are encouraging and were observed across tumor types
in heavily pretreated patients
T-DXd demonstrated clinically meaningful activity across a broad range of HER2-expressing solid tumors:
ORR: 37.1% in all patients and 61.3% in patients with IHC 3+
•
Durable responses: median DOR 11.3 months in all patients and 22.1 months in patients with IHC 3+
Durable responses led to clinically meaningful progression-free and overall survival outcomes:
•
PFS: 6.9 months in all patients and 11.9 months in patients with IHC 3+
OS: 13.4 months in all patients and 21.1 months in patients with IHC 3+
The safety of T-DXd was consistent with the known profile
DESTINY-Pan Tumor02 supports the potential role of T-DXd as a tumor-agnostic
therapy for patients with HER2-expressing solid tumors
DOR, duration of response; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; ORR, objective response rate;
OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan
51View entire presentation